Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus
For example, Coriat et al
In the diabetes pharmacotherapy area, a systematic review assessed that only 56.2% of patients with T2D continued their treatments at 1 year post-initiation [38]
Syringomas are benign (non-cancerous) growths of the sweat glands, specifically the eccrine ducts
Similar content being viewed by others Subjects Introduction Neurodegenerative diseases, such as Parkinsons (PD) and Alzheimers (AD), are largely due to neuronal damage often triggered by oxidative stress 1,2
The first batch of peptides up for discussion includes BPC-157 in ulcerative colitis, KPV in wound healing, and MOTs-C for obesity and osteoporosis